(IMTX) Immatics N.V. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IMTX) Immatics N.V. Complete Analysis Pack
Unlock the Full Ansoff Matrix for Deeper Strategic Insight
This Immatics N.V. Ansoff Matrix Analysis gives a concise, company-specific view of growth options across market penetration, market development, product development, and diversification to support strategy, investment, or planning—this page includes a real preview/sample of the analysis so you can judge format and depth before buying. Purchase the full version to receive the complete, ready-to-use Ansoff Matrix report.
Market Penetration
Phase I Progression of IMA201 in Solid Tumors
IMA201 is in Phase I and targets melanoma-associated antigens 4 or 8 in solid tumor patients, so Immatics N.V. is deepening its existing ACTengine base in U.S. oncology. This is a clear market penetration move: one current program, one current market, more attention in the same clinical niche. In 2025, Immatics held cash and cash equivalents of about $277 million, which supports continued clinical push without shifting away from its core platform.
Phase I Expansion of IMA202 Across Solid Tumor Types
IMA202 expands Immatics' reach within the same solid-tumor market by extending one platform into at least 2 new indications, squamous non-small cell lung carcinoma and hepatocellular carcinoma, after melanoma-associated antigen 1 is already validated in solid tumors. That broader use can lift patient coverage without changing the core asset, which is classic market penetration. Immatics reported cash, cash equivalents, and marketable securities of $353.9 million at year-end 2025, supporting this multi-indication push.
Phase I Focus on Recurrent and Treatment-Resistant Solid Tumors
IMA203 targets PRAME in adult patients with recurrent or treatment-resistant solid tumors, keeping Immatics in the same oncology market while narrowing to a high-need subgroup. Solid tumors make up about 90% of adult cancers, so the addressable base stays large even in niche use. This is a clear penetration play: the product and market are already in scope, but the unmet-need segment is tougher and more valuable.
MD Anderson Collaboration for ACTengine Clinical Reach
Immatics’ collaboration with MD Anderson Cancer Center deepens access to a top U.S. cancer site that treats 80,000+ patients a year. For ACTengine, this can lift referral flow, investigator support, and trial visibility in the same T-cell and TCR therapy market, so it fits market penetration rather than expansion into a new field.
- Existing market, deeper presence
- MD Anderson adds trial credibility
- Supports referral and investigator reach
Pharma Partnership Support for Current TCR Programs
Immatics' market penetration strategy is reinforced by two external pharma alliances with GlaxoSmithKline Intellectual Property Development Limited and Celgene Switzerland LLC, both aimed at novel adoptive cell therapies. These deals validate the ACTengine platform and help keep development inside the same oncology market, where Immatics is already active. That supports share gains in current TCR programs rather than pushing into a new market.
- Two major pharma alliances
- External validation for ACTengine
- Focus stays on oncology
- Strengthens current market share
Immatics Expands Deep in TCR Oncology with $353.9M in Cash
Immatics N.V. is using market penetration by pushing ACTengine deeper into the same solid-tumor and TCR oncology space with IMA201, IMA202, and IMA203. The 2025 cash position of $353.9 million gave it room to keep expanding within current programs and sites without changing the core market. MD Anderson and pharma alliances with GlaxoSmithKline and Celgene also support stronger share in the same field.
| Key 2025 data | Value |
|---|---|
| Cash and marketable securities | $353.9 million |
| MD Anderson patient base | 80,000+ per year |
| Solid tumors share of adult cancers | About 90% |
What is included in the product
Detailed Word Document
Maps Immatics N.V.’s growth options across existing and new products and markets
Editable Excel File
Provides a concise Immatics N.V. Ansoff Matrix view to quickly align growth strategy across products and markets.
Reference Sources
Provides a compact, verifiable source list that links each Ansoff growth path for Immatics N.V. to traceable primary and secondary references.
Market Development
IMA202 Use in Multiple Solid Tumor Indications
IMA202 fits market development because Immatics N.V. is taking the same asset into new solid-tumor segments, including squamous non-small cell lung carcinoma and hepatocellular carcinoma. That matters because NSCLC caused about 2.5 million new cases worldwide in 2022, while liver cancer cases were about 866,000. One drug, more patient pools, bigger addressable market.
IMA203 Reach Into Broader Adult Solid Tumor Segments
IMA203 targets adult patients with recurrent or treatment-resistant solid tumors, so Immatics can reuse one program across multiple cancers instead of one tumor type. That is market development because it expands reach into broader clinical segments, especially where unmet need is highest and response rates are often below 20% in late-line solid tumors. The wider adult solid tumor setting also enlarges the addressable use case for PRAME-positive disease.
IMA204 Entry Into Tumor Stroma Targeting
IMA204 is in preclinical development and targets tumor stroma cells, so Immatics is pushing its ACTengine TCR platform into a new solid-tumor niche. The platform stays the same, but the biological target changes, which fits market development: same engine, new disease segment. This matters because solid tumors still make up about 90% of adult cancers, and IMA204 broadens Immatics beyond its current T-cell focus.
MD Anderson Network for Wider Clinical Access
MD Anderson widens Immatics N.V.’s clinical reach by testing multiple T-cell and TCR-based adoptive cell therapies in a top cancer-center setting. That matters because MD Anderson treats a very large and diverse oncology population, so Immatics can reach more referral paths and patient types without changing the core programs. This is market development: the same pipeline is moved into a broader market venue.
- Expands trial access
- Broadens referral channels
- Reaches new patient groups
- Uses existing programs
Genmab Collaboration for Diverse Cancer Indications
Immatics and Genmab are applying Immatics’ T-cell engager science beyond ACTengine into broader oncology markets, which is classic market development: same know-how, new disease settings. Genmab’s bispecific platform helps widen the target pool across multiple cancer indications, not just one tumor type. In a global oncology market that topped $200 billion in 2025, that kind of indication expansion can create a much larger commercial path.
- Uses existing T-cell biology
- Expands into new cancer indications
- Broadens reach beyond ACTengine
- Targets a >$200B oncology market
Immatics Expands Into New Solid-Tumor Markets
Immatics N.V. is using the same TCR and T-cell platform to enter new solid-tumor segments, so Market Development fits. IMA202 extends into squamous NSCLC and HCC, while IMA203 widens use across recurrent solid tumors. MD Anderson and the Genmab deal also expand access and indication reach.
| Move | Market effect |
|---|---|
| IMA202 | New tumor types |
| IMA203 | Broader adult use |
| MD Anderson/Genmab | Wider reach |
Preview Before You Purchase
Immatics N.V. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.
Product Development
IMA204 Tumor Stroma Cell Program
IMA204 is a preclinical tumor stroma cell program, so it adds a new target class to Immatics N.V.’s solid-tumor pipeline and extends the company beyond its Phase I ACTengine candidates. In Ansoff Matrix terms, this is product development: a new product for an existing oncology market. Immatics is broadening from T-cell therapies into stromal targeting in 2025.
IMA401 Cancer Testis Antigen TCR Bispecific
IMA401 expands Immatics N.V.’s preclinical TCR Bispecifics line with a new format for the same solid tumor market. It targets cancer testis antigens, so it adds depth beyond the company’s ACTengine cell therapies. That makes it clear product development: a new product line aimed at the same cancer space.
IMA402 Solid Tumor TCR Bispecific Program
IMA402 is a preclinical TCR bispecific for solid tumors, so it fits product development: Immatics N.V. is adding a new product to an existing oncology market. It broadens the bispecific pipeline to 2 programs, alongside IMA401, and strengthens the company’s focus on solid tumor therapies. The step matters because it aims to expand one treatment area with a second differentiated asset before clinical proof-of-concept.
IMA301 Allogeneic Cellular Therapy Candidate
IMA301 is an allogeneic cellular therapy candidate, so it adds a new cell-therapy format next to Immatics N.V.'s autologous ACTengine approach. That makes it a clear product development move in Ansoff terms: same cancer-immunotherapy market, new product type. It broadens the pipeline beyond ACTengine and aims at off-the-shelf use, which can matter if manufacturing speed and scale improve.
- New product, same market
- Allogeneic, not autologous
- Expands cancer immunotherapy
IMA101 Cancer Treatment Program
IMA101 broadens Immatics N.V.’s oncology pipeline by adding another cancer treatment candidate to its existing market. That makes this a product development move, because it expands the menu of assets inside the same cancer therapy space, alongside ACTengine and TCR Bispecifics.
For 2025, the key value is pipeline depth: more shots on goal in a market where oncology remains the core focus and one approved asset still has to clear clinical risk.
- More candidates, same cancer market
- Adds breadth to the pipeline
- Fits product development in Ansoff
Immatics Expands Solid-Tumor Pipeline with 5 New Oncology Assets
Immatics N.V.’s product development in 2025 is about adding new oncology assets for the same solid-tumor market: 5 pipeline candidates now span ACTengine, TCR bispecifics, stromal targeting, and allogeneic therapy. That is classic Ansoff product development: new products, same cancer space.
| Item | Data |
|---|---|
| Pipeline breadth | 5 candidates |
| Main market | Oncology |
| Move | New products, same market |
Diversification
Genmab-Linked T-Cell Engaging Bispecific Immunotherapies
The Genmab collaboration moves Immatics N.V. from ACTengine cell therapies into T-cell engaging bispecific immunotherapies, so it adds a new product family and a new oncology modality market. That is classic diversification: new products for new cancer segments, not just more of the same pipeline. The move matters because bispecifics are a distinct drug class now advancing across solid tumors and hematologic cancers.
Allogeneic Cell Therapy via IMA301
IMA301 is Immatics N.V.’s allogeneic cell therapy candidate, so it moves beyond the company’s current autologous TCR-based ACT portfolio. This is true diversification in the Ansoff Matrix: a new product type in a new market segment, with a different development path and manufacturing model. Unlike patient-specific autologous therapy, allogeneic therapy can be made for broader use, which changes the commercial playbook.
Cancer Testis Antigen Bispecifics with IMA401
IMA401 is a cancer testis antigen bispecific built on Immatics' TCR Bispecific platform, so it moves the company into a new solid tumor immunotherapy class. Unlike ACTengine cell therapies, it is a different product with a different market path, which fits Ansoff diversification: new product, new market. In 2025, this kind of shift matters as bispecifics keep drawing capital and trials across oncology.
Tumor Microenvironment Targeting with IMA204
IMA204 moves Immatics N.V. into diversification because it targets tumor stroma cells, not the tumor-cell programs already in clinic. That opens a new biological target environment and a different therapeutic market, so the company is adding more than one product line. It also broadens risk across tumor biology, which is the core Ansoff signal here.
- Targets stroma, not tumor cells
- Opens a new market segment
- Expands beyond existing programs
- Fits Ansoff diversification
Multi-Partner Oncology Development Model
Immatics N.V. uses a multi-partner oncology model with GSK, MD Anderson, Celgene Switzerland, and Genmab, so development is spread across 4 collaboration lanes. That widens exposure across cancer targets and modalities, and it reduces reliance on one product or one partner. In Ansoff terms, this is clear diversification: new products, new programs, and adjacent channels at the same time.
Immatics Bets Big on New Oncology Modalities
Diversification in Immatics N.V.’s Ansoff Matrix is strongest where the Company moves into new oncology modalities and targets, not just new indications. The Genmab deal, IMA301, IMA401, and IMA204 each expand beyond the core ACTengine base into distinct product classes and market paths.
| Move | 2025/2026 signal |
|---|---|
| Genmab collaboration | 1 new modality lane |
| IMA301 | Allogeneic therapy |
| IMA401 | Bispecific class |
| IMA204 | Stroma target |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.